Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novo Nordisk's ultra long-acting insulin Tresiba has been recommended for approval by the European Medicines Agency in an important boost for the Danish drugmaker's key new product.
The European endorsement, announced by the London-based agency on Friday, comes after the diabetes treatment hit regulatory delays in the United States.
Tresiba, or degludec, is central to Novo's aim of ending Sanofi's dominance of the long-acting insulin market and the group said it expected to launch it in several European markets early next year, subject to final approval.
http://www.brecorder.com/world/europe/86945-eu-regulator-backs-novos-new-long-acting-insulin-.html
The European endorsement, announced by the London-based agency on Friday, comes after the diabetes treatment hit regulatory delays in the United States.
Tresiba, or degludec, is central to Novo's aim of ending Sanofi's dominance of the long-acting insulin market and the group said it expected to launch it in several European markets early next year, subject to final approval.
http://www.brecorder.com/world/europe/86945-eu-regulator-backs-novos-new-long-acting-insulin-.html